Glenmark Pharmaceuticals Expands Oncology Portfolio with Hengrui's HER2 Targeting ADC for Multiple Regions

Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd., has entered into an exclusive license and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC). Glenmark obtains exclusive rights to develop and commercialize Trastuzumab Rezetecan worldwide, excluding specific regions. The agreement includes an upfront payment of US$18 million and potential regulatory and commercial milestone payments of up to US$1.093 billion. Trastuzumab Rezetecan is a self-developed HER2-targeted ADC by Hengrui, approved in China for the treatment of HER2 (ERBB2) activating mutations in unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC). It is also under review for breast cancer indication in China and included in the NMPA’s Breakthrough Therapy Designation list for nine indications.